Evidence map›Paper›PMID 40790559›Full record

ArticleBMC gastroenterology2025

Long-term risk of irritable bowel syndrome associated with MASLD, MASLD type and different cardiometabolic risk factors: a large-scale prospective cohort study.

Yesheng Zhou, Zhirong Yang, Si Liu, Sian Xie, Qian Zhang, Shutian Zhang, Shengtao Zhu, Shanshan Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yesheng ZhouDepartment of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center for Digestive Disease, Beijing Digestive Disease Center, Beijing Key Laboratory for Precancerous Lesion of Digestive Disease, Beijing, 100050, China.
Zhirong YangShenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.
Si LiuDepartment of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center for Digestive Disease, Beijing Digestive Disease Center, Beijing Key Laboratory for Precancerous Lesion of Digestive Disease, Beijing, 100050, China.
Sian XieDepartment of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center for Digestive Disease, Beijing Digestive Disease Center, Beijing Key Laboratory for Precancerous Lesion of Digestive Disease, Beijing, 100050, China.
Qian ZhangDepartment of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center for Digestive Disease, Beijing Digestive Disease Center, Beijing Key Laboratory for Precancerous Lesion of Digestive Disease, Beijing, 100050, China.
Shutian ZhangDepartment of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center for Digestive Disease, Beijing Digestive Disease Center, Beijing Key Laboratory for Precancerous Lesion of Digestive Disease, Beijing, 100050, China.
Shengtao Zhu *Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center for Digestive Disease, Beijing Digestive Disease Center, Beijing Key Laboratory for Precancerous Lesion of Digestive Disease, Beijing, 100050, China. zhushengtao@ccmu.edu.cn.
Shanshan Wu *Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center for Digestive Disease, Beijing Digestive Disease Center, Beijing Key Laboratory for Precancerous Lesion of Digestive Disease, Beijing, 100050, China. shanshanwu@ccmu.edu.cn.

Funding

Beijing Nova Program 20230484349National Key Research and Development Program of China 2022YFC2504002, 2022YFC2504003
6 · The paper itself

Abstract

backgroundDespite the increased irritable bowel syndrome (IBS) risk associated with hepatic steatosis demonstrated in prior evidence, it is still unclear whether the newly coined metabolic dysfunction-associated steatotic liver disease (MASLD), could in reverse impact IBS development. We prospectively assessed the association of MASLD, MASLD type and different cardiometabolic risk factors (CMRFs) with incident IBS in a nationwide population-based cohort.

methodsParticipants free of IBS at baseline in UK Biobank were included (N = 380,619). MASLD, MASLD type [pure MASLD, MASLD with increased alcohol intake (MetALD)] and CMRFs were defined based on the new criteria in America and Europe. Cox proportional hazard model was used to assess the associated risk of incident IBS.

resultsOverall, 143,857 (37.8%) had MASLD at baseline. During a median 13.2-year follow-up, 7329 incident IBS cases were identified. Compared with normal individuals, MASLD patients had an 11% elevated risk of IBS (HR = 1.11, 95%CI: 1.04-1.20). The increased risk was present in both pure MASLD (HR = 1.12, 1.03-1.21) and MetALD (HR = 1.26, 1.09-1.45) patients. Moreover, a substantially greater risk of IBS was observed as the number of CMRFs increased in MASLD patients (P

conclusionsMASLD, either pure MASLD or MetALD, was associated with an increased risk of incident IBS, with greater risk with more cardiometabolic risk factors, suggesting management of MASLD may help prevent IBS.

Indexed as

Cardiometabolic Risk FactorsIrritable Bowel SyndromeAdultAgedAlcohol DrinkingFemaleHumansIncidenceMaleMetabolic SyndromeMiddle AgedProportional Hazards ModelsProspective StudiesRisk FactorsUnited KingdomCohort studiesIrritable bowel syndromeMetabolic dysfunction-associated steatotic liver disease

Identifiers

PMID40790559
PMCPMC12337495

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.